Curated News
By: NewsRamp Editorial Staff
August 26, 2026

VolitionRx's Nu.Q NETs Biomarker Predicts Sepsis Mortality

Discuss on SubstackView history of this news story on GitHub
Original Source

TLDR

  • VolitionRx's Nu.Q NETs biomarker predicts sepsis mortality, offering a competitive edge in the $2.8B market.
  • VolitionRx's peer-reviewed study in Critical Care Medicine shows Nu.Q NETs H3.1 levels correlate with sepsis severity and kidney injury.
  • VolitionRx's Nu.Q NETs test could enable earlier sepsis intervention, improving survival and quality of life for patients.
  • VolitionRx's Nu.Q NETs biomarker independently predicts 28-day mortality and need for renal replacement in sepsis patients.

Impact - Why it Matters

This news is important because sepsis is a life-threatening condition with high mortality rates, and early risk stratification can significantly improve patient outcomes. The Nu.Q NETs biomarker offers a simple blood test that could help clinicians identify high-risk patients early, allowing for timely interventions and personalized treatment. This could not only save lives but also reduce healthcare costs by preventing severe complications like acute kidney injury and the need for renal replacement therapy. For VolitionRx, this publication strengthens their commercial prospects in a $2.8 billion market, potentially accelerating adoption and licensing deals. For patients and healthcare providers, this represents a step toward more precise and proactive sepsis management, ultimately improving survival and quality of life.

Summary

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed paper in Critical Care Medicine demonstrating that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. The study found significantly higher Nu.Q NETs H3.1 levels in septic shock patients compared to sepsis patients, and a dose-response relationship with acute kidney injury severity. An independent editorial in the same journal also examined H3.1 nucleosomes as a potential marker of NET-mediated organ injury, further validating the biomarker's potential clinical utility.

The findings support Volition's ongoing commercial and licensing discussions for Nu.Q NETs, its nucleosome quantification technology designed to detect diseases associated with NETosis. The company believes the test could help clinicians anticipate disease progression, guide treatment decisions, and monitor patients over time across acute and chronic conditions. Volition cited a total addressable market of $2.8 billion for the technology. Dr Andrew Retter, Medical Consultant at Volition, highlighted the potential of Nu.Q NETs as a "treatable, trackable trait" that could lead to new ways of treating sepsis, improving patient survival and quality of life.

Volition is focused on advancing epigenetics and developing simple, cost-effective blood tests for early detection and monitoring of diseases, including certain cancers and NETosis-related conditions like sepsis. The company's research and development are based in Belgium, with offices in the U.S. and London. The full press release is available at https://ibn.fm/RErhc. For more information about Volition, visit their website at https://volition.com/.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx's Nu.Q NETs Biomarker Predicts Sepsis Mortality

Blockchain registration record for this content